In 2013, Aileen, a investor in Cowboy Ventures in the United States, collectively referred to the “unicorn†as a “unicorn†that was established in the market for a short period of time (not more than 10 years) and valued at more than $1 billion by investors or valuation agencies. Thus, the term "unicorn" originated in the United States and gradually spread throughout the world. After the unicorn Mobai in the travel field was acquired by the US group, is it true that the acquisition is “harvesting†or “falling into the bag†for the company, is it just like Mobay CEO Hu Wei said: “Capital support for you, future you It is necessary to double back." The discussion of these topics in the capital market is rampant. It is true that the growth of unicorn companies cannot be separated from the operation of capital. In investment, not only should we pay attention to how to enter a project. For venture capital funds, it is more important to withdraw. The exit mechanism is the key to venture capital to avoid risks, recover investment and obtain income. With the liberalization of A-shares, IPO seems to be the ultimate goal of medical health unicorns. Due to its high return on investment, IPO has become the ideal exit method for investors. But whether at home or abroad, IPOs have a small test of the company's continued profitability and financial capabilities. In the valuation of IPOs of various exchanges in the arterial network, the valuations of overseas market companies such as the New York Stock Exchange and Nasdaq are in the middle level. The high-valued unicorns become investors and love again. Hate the subject. Compared with the grand occasion of IPO in 2013 and 2014, the return rate of VC/PE in investment has dropped accordingly. Therefore, correspondingly, the exit strategy is fully bet on IPOs, and is also adjusted to mergers and acquisitions, equity repurchases and other methods in parallel. According to CBinsights' Unicorn database, 19 of the medical unicorns from 2010 to 2018 were withdrawn through mergers and acquisitions. What are the characteristics of these companies? The arterial network analyzes the data and explores the logic behind the exit of the medical unicorn. Acquisition and exit of the unicorn enterprise analysis According to the Unicorn Tracker data, in the field of medical health, there have been 32 companies that have exited through various methods such as IPO and Acquired since 2009, of which 11 companies have IPOs with a total valuation of 169.3. In the case of US$100 million, the number of companies that withdrew was 18, and the total value of the exit was US$47.54 billion. Based on the above data, IPOs and mergers and acquisitions become the mainstream choice for capital and enterprises when they withdraw. According to statistics, companies listed on the Nasdaq spend an average of more than 1 million US dollars, and the total cost paid for listing accounts for 8% to 25% of the funds raised. These expenses mainly include publicity expenses, legal fees, and audits. Fees, financial advisory fees, underwriter fees and direct market expenses. The amount of listing fees depends on the size of the company, the method of fundraising and the amount of fundraising. Therefore, foreign unicorn companies do not exclude quicker monetary exits, and the amount exceeds the amount of funds raised by the IPO. Unicorn companies that have withdrawn in recent years (source: CBinsights) Industry distribution industry statistics (source: CBinsights) Due to the long period of IPO realization, enterprises need to invest more funds during this period. Therefore, in the past two decades, M&A has been the theme of the development of life science and medical industry worldwide, in the above-mentioned unicorn mergers and acquisitions. Among them, 15 projects belong to the bio-pharmaceutical sector, accounting for 75% of the total, with a total valuation of 42.29 billion yuan. There are fewer medical devices and medical services, and the number is 3 and 1 respectively. The valuations at the time of exit are 3.9 billion and 1.7 billion respectively.
Medical Cold Patch
Throat Pain Relief Patch,Throat Pain Relief Pad,Throat Pain Relief Plaster,Antitussive Patch Shandong XiJieYiTong International Trade Co.,Ltd. , https://www.sdxjmedical.com
Throat Pain Relief Patch
[Name] Medical Cold Patch
[Package Dimension] 36 round pieces
The pain relief patch is composed of three layers, namely, backing lining, middle gel and protective film. It is free from pharmacological, immunological or metabolic ingredients.
[Scope of Application] For cold physiotherapy, closed soft tissue only.
[Indications]
The patches give fast acting pain relief for acute and chronic tonsillitis.
[How To Use a Patch]
Please follow the Schematic Diagram. One piece, one time.
The curing effect of each piece can last for 6-8 hours.
[Attention]
Do not apply the patch on the problematic skin, such as wounds, eczema, dermatitis,or in the eyes. People allergic to herbs and the pregnant are advised not to use the medication. If swelling or irritation occurs, please stop using and if any of these effects persist or worsen.notify your doctor or pharmacist promptly. Children using the patch must be supervised by adults.
[Storage Conditions] Store below 30c in a dry place away from heat and direct sunlight.